Skip to main content

Notice for ranibizumab (Novartis Pharmaceuticals Australia Pty Ltd)

Active ingredients
ranibizumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection solution
Indication
For the treatment of preterm infants with retinopathy of prematurity (ROP)
Therapeutic area
Ophthalmology

Help us improve the Therapeutic Goods Administration site